Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus chemotherapy in advanced NSCLC (CHOICE-01)
NCT03856411Phase 3Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Mar 2019
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Mar 2019; status: completed.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03856411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03856411.